Oncimmune Inks Chinese Licensing Deal for Diagnostics Platform

Jan 03, 2018

|

NEW YORK (360Dx) – Cancer detection firm Oncimmune announced on Tuesday that it has signed a licensing agreement for its EarlyCDT autoantibody-based diagnostics platform in China.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Oncimmune Inks Chinese Licensing Deal for Diagnostics Platform

To read the full story....

Breaking News

Angle Files De Novo FDA Submission for CTC Collection Device in Breast Cancer

LabCorp, Genfit Partner to Commercialize Liver Disease Diagnostic Test

Hologic Receives FDA Emergency Use Authorization for SARS-CoV-2 Testing of Asymptomatic Individuals

Quotient Limited Gets FDA Emergency Use Authorization for Coronavirus Antibody Test

Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

What's Popular?

Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Sponsorships